Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lotemax in Sjogren's Disease
NCT02322528Completed
- Sponsor
- University of Rochester
- Start
- Apr 2014
- Primary completion
- Aug 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of loteprednol etabonate in Sjogren's syndrome, sponsored by University of Rochester. Primary endpoints: Ocular Surface Temperature of Both Eyes at 2 weeks and Visual Quality at 2 weeks. Started Apr 2014; status: completed.
02
Drugs
loteprednol etabonate
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT02322528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322528.